Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + portal vein tumor thrombosis SBRT + TKIs + PD-1 inhibitors for advanced hepatocellular carcinoma with VP3-VP4 portal vein tumor thrombosis
ChiCTR2400080802Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate and Adverse events. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
durvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400080802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080802.